logo

For the Inventor, By the Inventor

North Caldwell, NJ, United States of America

Enrico G Baggiolini

USPTO Granted Patents = 28


Average Co-Inventor Count = 3.4

ph-index = 8

Forward Citations = 233(Granted Patents)


Location History:

  • Nutley, NJ (US) (1976 - 1982)
  • Bloomfield, NJ (US) (1980 - 1983)
  • North Caldwell, NJ (US) (1985 - 1993)

Company Filing History:

goldMedal28 out of 4,948 
 
Hoffmann-la Roche Inc.
 patents

Years Active: 1976-1993

Loading Chart...
Loading Chart...
28 patents (USPTO):Explore Patents
1. 5247123 - Deuterated analogs of 1,25-dihydroxycholecalciferol (1993-09-21),
2. 5149846 - Deuterated analogs of 1,25-dihydroxycholecalciferol (1992-09-22),
3. 5120722 - Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating (1992-06-09),
4. 5110958 - Compounds, process and intermediates (1992-05-05),
5. 5039671 - Trifluorinated-1.alpha.,25S-dihydroxy vitamin D3 compounds (1991-08-13),
6. 4906785 - Novel trifluorinated vitamin D3 intermediates (1990-03-06),
7. 4898855 - Deuterated analogs of 1,25-dihydroxycholecalciferol (1990-02-06),
8. 4804502 - Vitamin D compounds (1989-02-14),
9. 4632784 - Process for the preparation of (1986-12-30),
10. 4613594 - Fluorinated vitamin D.sub.3 compounds (1986-09-23),
11. 4612308 - 25,26-Dehydro-1.alpha.,23(S,R)-dihydroxycholecalciferol and its epimers (1986-09-16),
12. 4595776 - Synthesis of 1.alpha.,25-dihydroxyergocalciferol (1986-06-17),
13. 4594432 - Process for the synthesis of 1.alpha.,23(S),25-trihydroxycholecalciferol (1986-06-10),
14. 4508651 - Synthesis of 1.alpha.,25-dihydroxyergocalciferol (1985-04-02),
15. 4382031 - Intermediates for the preparation of biotin (1983-05-03),

Title: Enrico G. Baggiolini: Innovator in Vitamin D Analog Research

Introduction

Enrico G. Baggiolini, based in North Caldwell, NJ, is a prominent inventor known for his contributions to the field of pharmaceutical sciences. With an impressive portfolio of 28 patents, Baggiolini has focused on innovations that aim to improve health outcomes, particularly in the treatment of osteoporosis and skin conditions.

Latest Patents

Among his latest patents, Baggiolini has developed deuterated analogs of 1,25-dihydroxycholecalciferol. This invention encompasses processes and intermediates for the preparation of these vitamin D analogs. The end products are particularly beneficial for treating osteoporosis, as well as cutaneous inflammations such as psoriasis and contact dermatitis. The innovative nature of this research positions Baggiolini at the forefront of therapeutic advancements in vitamin D applications.

Career Highlights

Baggiolini's career is marked by his role at Hoffmann-La Roche Inc., a renowned global healthcare company committed to innovative pharmaceuticals. His work has significantly impacted the pharmaceutical landscape, contributing to the understanding and application of vitamin D in various therapeutic contexts.

Collaborations

Throughout his career, Baggiolini has collaborated with esteemed colleagues such as Milan R. Uskokovic and Hsi L. Lee. These collaborations have allowed for the cross-pollination of ideas and expertise, fostering advancements in the research and development of vitamin D analogs.

Conclusion

Enrico G. Baggiolini exemplifies the spirit of innovation in the pharmaceutical industry. His advancements in deuterated vitamin D analogs not only highlight his expertise but also contribute to significant improvements in therapeutic options for patients suffering from osteoporosis and skin ailments. As research continues, Baggiolini's work will likely remain influential in shaping future healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…